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We read with interest the article by Choi, et al.1 (RA1), entitled “The clinical use-
fulness of the SD bioline influenza antigen test for detecting the 2009 influenza A 
(H1N1) virus.” In this study, the authors explained that the rapid antigen test 
(RAT) cannot be recommended for general use in all patients with influenza-like 
illnesses because of its low sensitivity. However, there were two very similar pre-
vious reports (RA2 Choi, et al.,2 RA3 Lee, et al.3) that demonstrated high RAT 
sensitivity with the same RAT kit previous to the results presented by Choi, et al.1 
(RA1). The sensitivity of the two previous reports was above 75.6%.
RAT kits are used to screen patients with suspected influenza and offer the ad-
vantage of providing a timely result that can influence clinical decision making.4 
RAT can be used in many hospital laboratories, emergency departments, and pri-
vate clinics easily. RAT can also help to reduce unnecessary diagnostic testing, fa-
cilitate antiviral treatment, and decrease the inappropriate use of antibiotics. How-
ever, the clinical sensitivity of RAT has been shown to be poor for 2009 H1N1 
influenza, demonstrating an accuracy of 11.1% to 51%.4 Also, viral concentrations 
in clinical samples can influence the sensitivity of RAT. Thus, the collection time 
of the samples may be an important factor for the accuracy of RAT.5  
We compared two previous reports on RAT sensitivity and specificity. We used 
the real-time reverse transcription-polymerase chain reaction to confirm the 2009 
H1N1 influenza using nasopharyngeal or throat swap sample.  RAT was per-
formed using the SD Bioline Influenza A/B/A (H1N1) Pandemic kit (Standard Di-
agnosis, Inc., Suwon, Korea). There are four detection lines of the RAT; influenza 
A, influenza B, 2009 H1N1, and control (1). Samples were classified according to 
the hours that elapsed after the first symptoms appeared to when they were collect-
ed in RA1 and RA3. They were classified into ≤24 hours (D1), 24 to 48 hours 
(D2), 48 to 72 hours (D3), and after (D4) in RA1, and ≤24 hours (D1), 24 to 48 
hours (D2), 48 to 72 hours (D3), 72 to 96 hours (D4), and 96 to ≤168 hours (D5) 
in RA3. RA2 did not analyze the time-dependent sensitivity of RAT. 
The overall sensitivity of RAT was 44% for RA1 (117/266), 77.0% for RA2 
(241/313), and 75.6% for RA3 (482/637). The specificity of RAT was 99.9%, 
100% and 99.3%, respectively. The positive predictive value (PPV) were 99.2% 
(RA1) and 100% (RA2). The negative predictive value (NPV) were 81.8% (RA1) 
and 86% (RA2). The time dependent sensitivity of RAT at D1, D2, D3, D4-5 was Clinical Usefulness of Rapid Antigen Test 
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To the editor,
We are grateful for the comments on the issue of the clin-
ical usefulness of the rapid antigen test (RAT) for influenza. 
The RAT has an advantage of providing clinicians with an 
answer within minutes. However, the usefulness of the test 
is debatable due to its inconsistent accuracy and, especially, 
its highly variable sensitivity.
In our report, the sensitivity of the SD Bioline Influenza 
Antigen Test® (Standard Diagnostic, Inc., Suwon, Korea) 
was 44.0% and the specificity was 99.9%.1 The RAT kit 
used in our study was developed for seasonal influenza vi-
rus circulating before the 2009 pandemic influenza and was 
not specialized for the A(H1N1)pdm09 virus. In compari-
son, the SD Bioline Influenza Antigen A/B/A (H1N1) Pan-
demic® kit (Standard Diagnostic, Inc., Suwon, Korea), 
which was used in the other two studies, was developed for 
the specific detection of the A(H1N1)pdm09 virus.2,3 There-
fore, a head-to-head comparison of our study and the other 
two studies is inappropriate. The new test kit may have im-
proved accuracy for detecting A(H1N1)pdm09 virus.
A point to be considered, other than the difference of the 
RAT kits, is careful interpretation of the RAT results in 
terms of deciding antiviral treatment or infection control 
measures. With a positive result of the RAT, a clinician can 
confidently diagnose influenza and begin antiviral therapy 
as well as appropriate infection control measures because 
the specificity of the RAT is very high. However, a negative 
result of the RAT has a reasonable likelihood of being false 
negative even if the sensitivity of the test is 77.0%. If a neg-
ative result is reported by the RAT in a patient with an in-
fluenza-like illness and who is at a high risk for developing 
influenza complications, a clinician cannot exclude influen-
za and defer the initiation of antiviral therapy or infection 
control measures either. That is, a clinician comes to decid-
ing on initiating early antiviral therapy or infection control 
measures, especially for high risk patients, on the basis of 
61.3%, 67.9%, 51.1%, and 11.1% in RA1 and 75.0%, 
76.8%, 79.9%, 77.4%, 67.3% in RA3.  
Early diagnosis and treatment is very important to treating 
influenza, because if the diagnosis is delayed, complications 
can increase. In particular, the 2009 H1N1 influenza virus in-
volves the lower respiratory tract, which can lead to pneumo-
nia. Choi, et al. (RA1) insist that the RAT kit cannot be rec-
ommended for general use in all patients with influenza-like 
illness because of its low sensitivity. However, the sensitivity 
of the SD Bioline Influenza A/B/A (H1N1) Kit was relatively 
good in the two previous studies. The sensitivity of RAT was 
relatively high in RA2 (77.0%) and RA3 (75.6%). The time-
dependent sensitivity of RAT was evaluated to increase the 
sensitivity in RA1 and RA3. Through these results we can 
increase the sensitivity of the RAT kit to detect influenza vi-
rus in clinical settings everywhere. 
The RAT kit is known as a point-of-care test, because they 
have a fast turnaround time within 30 minutes and require 
minimal training to perform. However, major problem of 
RAT was low sensitivity for H1N1 virus. In this study, ac-
cording to the results of RA2 and RA3, we can use the SD 
Bioline Influenza A/B/A (H1N1) Kit in general clinical set-
tings with relatively high sensitivity, convenience, rapidity, 
portability, and ease of performance in all situations. To 
know the exact sensitivity of the SD RAT kit, we need fur-
ther studies with more samples. However, we suggest that 
the SD Bioline Influenza A/B/A (H1N1) Kit can be used in 
general clinical settings for cases where samples are ob-
tained from patients who visit a hospital within 72 hrs of 
symptom onset, because three studies have reported rela-
tively high sensitivity of at least 60.4% (RA1).
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clinical judgment regardless of the result of the RAT. Of 
course, other diagnostic tests, real-time reverse transcrip-
tase polymerase chain reaction (rRT-PCR) or viral culture, 
have their own limitations. Their most obvious limitation is 
the longer time required for reporting results. Antiviral ther-
apy is most effective when it is initiated within 48 hours af-
ter onset of influenza symptoms.4,5 Infection control mea-
sures should be initiated immediately after recognition of 
an influenza case, because influenza viruses can be trans-
mitted from the day before symptoms begin.6 For the best 
management of influenza patients, antiviral therapy or in-
fection control measures cannot be delayed while the re-
sults of rRT-PCR or viral culture are awaited. Requiring 
high cost, specialized equipment and expertise is another 
disadvantage of these tests. When considering the limita-
tions of laboratory diagnostic tests, recent guidelines for in-
fluenza management recommended that antiviral therapy 
should not be delayed while waiting for a definitive influen-
za test result and negative results from RAT should not be 
used to make treatment or infection-control decisions.7-9 
The influenza A (H3N2) virus was the predominant influ-
enza virus subtype during the 2011-2012 season in Korea, 
up to the 8th week of 2012.10 For recommending the RAT in 
general clinical settings, therefore, we should consider the 
usefulness of the RAT in detecting seasonal influenza virus 
as well as the A(H1N1)pdm09 virus. Yoo, et al.11 reported 
that the sensitivity of the SD Bioline Influenza Antigen Test® 
(Standard Diagnostic, Inc., Suwon, Korea) was 61.9% for 
the influenza A virus and 54.5% for the influenza B virus, 
respectively. A meta-analysis including several RAT kits 
also reported a low sensitivity for RAT as 62.3% (95% CI, 
57.9% to 66.6%) and concluded that influenza can be ruled 
in but not ruled out through the use of RAT.12
In conclusion, though the RAT has some advantages, we 
still hold the viewpoint that RAT results need to be interpret-
ed carefully in general clinical practices and development of 
improved RAT kits or other diagnostic methods is necessary.